Financials data is unavailable for this security.
View more
Year on year Eterna Therapeutics Inc has grown net income from a loss of -24.58m to a smaller loss of -21.67m primarily through revenue growth (0.00 to 68.00k). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales , the -- growth in revenues contributed enough to still see net income improve.
Gross margin | -111.11% |
---|---|
Net profit margin | -14,765.43% |
Operating margin | -13,572.84% |
Return on assets | -51.20% |
---|---|
Return on equity | -- |
Return on investment | -62.39% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Eterna Therapeutics Inc fell by 3.87m. Cash Flow from Financing totalled 16.56m or 24,347.06% of revenues. In addition the company used 20.41m for operations while cash used for investing totalled 19.00k.
Cash flow per share | -4.40 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -1.58 |
---|---|
Tangible book value per share | -1.95 |
More ▼
Balance sheet in USDView more
Current ratio | 0.3732 |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 10.22 |
More ▼